Wall Street analysts predict that NeuBase Therapeutics, Inc. (NASDAQ:NBSE – Get Rating) will announce earnings per share of ($0.26) for the current quarter, Zacks reports. Zero analysts have provided estimates for NeuBase Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.24) and the lowest estimate coming in at ($0.28). NeuBase Therapeutics posted earnings of ($0.24) per share during the same quarter last year, which would indicate a negative year over year growth rate of 8.3%. The company is expected to announce its next earnings results on Monday, January 1st.
On average, analysts expect that NeuBase Therapeutics will report full year earnings of ($0.97) per share for the current fiscal year, with EPS estimates ranging from ($1.09) to ($0.89). For the next financial year, analysts forecast that the firm will report earnings of ($1.17) per share, with EPS estimates ranging from ($1.31) to ($1.03). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover NeuBase Therapeutics.
NeuBase Therapeutics (NASDAQ:NBSE – Get Rating) last released its earnings results on Thursday, February 10th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.01.
Shares of NBSE stock traded down $0.01 on Friday, hitting $1.68. The stock had a trading volume of 200 shares, compared to its average volume of 133,254. The business has a 50 day moving average of $1.62 and a 200 day moving average of $2.53. NeuBase Therapeutics has a 12-month low of $1.21 and a 12-month high of $6.69. The stock has a market cap of $55.05 million, a price-to-earnings ratio of -1.72 and a beta of 0.53.
Large investors have recently added to or reduced their stakes in the business. AIGH Capital Management LLC bought a new position in NeuBase Therapeutics in the fourth quarter valued at $2,811,000. Millennium Management LLC grew its position in shares of NeuBase Therapeutics by 276.2% in the 2nd quarter. Millennium Management LLC now owns 174,020 shares of the company’s stock worth $834,000 after buying an additional 127,767 shares during the period. Morgan Stanley increased its position in NeuBase Therapeutics by 393.9% during the 2nd quarter. Morgan Stanley now owns 119,678 shares of the company’s stock valued at $574,000 after buying an additional 95,447 shares in the last quarter. Stonepine Capital Management LLC boosted its holdings in shares of NeuBase Therapeutics by 253.2% during the 3rd quarter. Stonepine Capital Management LLC now owns 109,742 shares of the company’s stock valued at $396,000 after acquiring an additional 78,672 shares during the last quarter. Finally, CM Management LLC bought a new position in shares of NeuBase Therapeutics during the 3rd quarter valued at $271,000. 31.22% of the stock is currently owned by hedge funds and other institutional investors.
NeuBase Therapeutics Company Profile (Get Rating)
NeuBase Therapeutics, Inc is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm’s therapies are built on a proprietary platform called PATrOL that encompasses a novel peptide-nucleic acid antisense oligonucleotide technology combined with novel delivery shuttles that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines.
- Get a free copy of the StockNews.com research report on NeuBase Therapeutics (NBSE)
- OrganiGram’s Turnaround Begins To Blossom
- Three Dividend Stocks With Growth Potential
- Exelon Stock Still Has Extraordinary Upside
- Greenbrier Companies Stock has Green in its Future
- Insiders Are Selling Palo Alto Networks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NeuBase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuBase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.